Glucagon in heart failure and in cardiogenic shock. Experience in 50 patients.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001794:Blood Pressure; D001835:Body Weight; D004071:Digitalis Glycosides / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D011183:Postoperative Complications / Q000188:drug therapy; D011346:Prochlorperazine / Q000627:therapeutic use; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D013148:Spironolactone / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004071:Digitalis Glycosides; D013148:Spironolactone; D005665:Furosemide; D005934:Glucagon; D011346:Prochlorperazine